几种经美国食品药品监督管理局批准的药物在体外能有效抑制新型冠状病毒感染。
Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro.
作者信息
Xiong Hua-Long, Cao Jia-Li, Shen Chen-Guang, Ma Jian, Qiao Xiao-Yang, Shi Tian-Shu, Ge Sheng-Xiang, Ye Hui-Ming, Zhang Jun, Yuan Quan, Zhang Tian-Ying, Xia Ning-Shao
机构信息
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences and School of Public Health, Xiamen University, Xiamen, China.
Department of Clinical Laboratory, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
出版信息
Front Pharmacol. 2021 Feb 5;11:609592. doi: 10.3389/fphar.2020.609592. eCollection 2020.
To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 μM.
为了确定可能用于治疗新型冠状病毒肺炎（COVID-19）的药物，使用可靠的假病毒试验评估了1403种美国食品药品监督管理局（FDA）批准的药物的效力，并通过 authentic SARS-CoV-2试验进一步确认了候选药物。四种化合物，氯米芬（柠檬酸盐）、伏硫西汀、伏硫西汀（氢溴酸盐）和阿塞那平（盐酸盐），在假病毒试验和真实病毒试验中均显示出强效抑制作用。氯米芬（柠檬酸盐）、伏硫西汀和阿塞那平（盐酸盐）的组合比单独使用时更有效，半数抑制浓度（IC50）为0.34μM。
Zotero 插件